Literature DB >> 9536937

Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment.

A el-Nujumi1, C Williams, J E Ardill, K Oien, K E McColl.   

Abstract

BACKGROUND: Both proton pump inhibitor drug treatment and Helicobacter pylori infection cause hypergastrinaemia in man. AIMS: To determine whether eradicating H pylori is a means of reducing hypergastrinaemia during subsequent proton pump inhibitor treatment.
METHODS: Patients with H pylori were randomised to treatment with either anti-H pylori or symptomatic treatment. One month later, all received four weeks treatment with omeprazole 40 mg/day for one month followed by 20 mg/day for six months. Serum gastrin concentrations were measured before and following each treatment.
RESULTS: In the patients randomised to anti-H pylori treatment, eradication of the infection lowered median fasting gastrin by 48% and meal stimulated gastrin by 46%. When gastrin concentrations one month following anti-H pylori/symptomatic treatment were used as baseline, omeprazole treatment produced a similar percentage increase in serum gastrin in the H pylori infected and H pylori eradicated patients. Consequently, in the patients in which H pylori was not eradicated, median fasting gastrin concentration was 38 ng/l (range 26-86) at initial presentation and increased to 64 ng/l (range 29-271) after seven months omeprazole, representing a median increase of 68% (p < 0.005). In contrast, in the patients randomised to H pylori eradication, median fasting gastrin at initial presentation was 54 ng/l (range 17-226) and was unchanged after seven months omeprazole at 38 ng/l (range 17-95).
CONCLUSION: Eradicating H pylori is a means of reducing the rise in gastrin during subsequent long term omeprazole treatment. In view of the potential deleterious effects of hypergastrinaemia it may be appropriate to render patients H pylori negative prior to commencing long-term proton pump inhibitor treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9536937      PMCID: PMC1727003          DOI: 10.1136/gut.42.2.159

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

1.  Gastric histology and plasma gastrin response to a meal in patients with duodenal ulcer disease after five years treatment with ranitidine.

Authors:  J G Penston; J S Dixon; S A Selway; K G Wormsley
Journal:  Aliment Pharmacol Ther       Date:  1990-08       Impact factor: 8.171

2.  Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole.

Authors:  G R Betton; C S Dormer; T Wells; P Pert; C A Price; P Buckley
Journal:  Toxicol Pathol       Date:  1988       Impact factor: 1.902

3.  Serum gastrin levels during long-term omeprazole treatment.

Authors:  H Koop; M Klein; R Arnold
Journal:  Aliment Pharmacol Ther       Date:  1990-04       Impact factor: 8.171

4.  Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis.

Authors:  J B Jansen; E C Klinkenberg-Knol; S G Meuwissen; J W De Bruijne; H P Festen; P Snel; A E Lückers; I Biemond; C B Lamers
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

Review 5.  Is hypergastrinaemia dangerous to man?

Authors:  W Creutzfeldt; R Lamberts
Journal:  Scand J Gastroenterol Suppl       Date:  1991

Review 6.  Biochemistry and physiology of gastrointestinal somatostatin.

Authors:  M R Lucey; T Yamada
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

7.  Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication.

Authors:  J Weil; G D Bell; K Powell; A Morden; G Harrison; P W Gant; P H Jones; J E Trowell
Journal:  Aliment Pharmacol Ther       Date:  1991-06       Impact factor: 8.171

8.  Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects.

Authors:  K E McColl; G M Fullarton; R Chittajalu; A M el Nujumi; A M MacDonald; S W Dahill; T E Hilditch
Journal:  Scand J Gastroenterol       Date:  1991-03       Impact factor: 2.423

9.  Helicobacter pylori infection induces a decrease in immunoreactive-somatostatin concentrations of human stomach.

Authors:  H Kaneko; K Nakada; T Mitsuma; K Uchida; A Furusawa; Y Maeda; K Morise
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

10.  24-hour intragastric acidity and plasma gastrin during long-term treatment with omeprazole or ranitidine in patients with reflux esophagitis.

Authors:  T Lind; C Cederberg; J P Idström; H Lönroth; L Olbe; L Lundell
Journal:  Scand J Gastroenterol       Date:  1991-06       Impact factor: 2.423

View more
  4 in total

1.  Helicobacter pylori infection and gastrointestinal hormones:a review.

Authors:  Xiang-Qian Huang
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist?

Authors:  Hiroshi Hashimoto; Tetsuya Kushikata; Mihoko Kudo; Kazuyoshi Hirota
Journal:  J Gastroenterol       Date:  2007-04-26       Impact factor: 7.527

Review 3.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 4.  Towards Understanding of Gastric Cancer Based upon Physiological Role of Gastrin and ECL Cells.

Authors:  Helge Waldum; Patricia Mjønes
Journal:  Cancers (Basel)       Date:  2020-11-22       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.